AbbVie

AbbVie

Yahoo Finance • 12 hours ago

What iShares Core High Dividend (HDV) Bought: Exxon Leads on Nov. 2

This article first appeared on GuruFocus. iShares Core High Dividend ETF (HDV) was the sole ETF buying on Monday, Nov. 2, with no funds selling. HDV added $134.1 million in gross trades, lifting 72 positions and trimming none, against $16... Full story

Yahoo Finance • 12 hours ago

Capital Group Cons. Equity (CGCV) Adds Microsoft and Philip Morris on Monday

This article first appeared on GuruFocus. Capital Group Conservative Equity ETF (CGCV) recorded net buying of $158.6 million on Monday, Nov. 2, with gross ETF activity matching that figure as the fund made no sales. All 69 positions that... Full story

Yahoo Finance • 12 hours ago

State Street Health Care SPDR (XLV) Adds Eli Lilly and J&J on Nov. 2

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) was buying on Monday, with 60 positions increased and none decreased, and no ETFs selling. The fund's ETF activity totaled $175.3 million boug... Full story

Yahoo Finance • 14 hours ago

Nxera Pharma Revises Consolidated Financial Forecast for the Year Ending 31 December 2026

Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. ("Nxera" or the "Company") today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, previously anno... Full story

Yahoo Finance • 14 hours ago

Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease

Nxera Pharma Nxera to receive US$100 million upfront and be eligible for up to US$1.37 billion in development and commercial milestone payments, plus tiered royalties. NXE0033744, an investigational oral EP4 receptor agonist discovered us... Full story

Yahoo Finance • yesterday

Most and least shorted mid- to mega-cap healthcare stocks at the end of October

Short interest data from late October 2026 highlights deeply divided investor sentiment across the healthcare sector. Strong bearish bets remain heavily concentrated in high-volatility biotechnology, equipment, and digital health names, wi... Full story

Yahoo Finance • yesterday

Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026

– Nine abstracts will be presented, including new data from Phase 4 research examining aesthetic treatment following medical weight loss, with a focus on patient satisfaction and psychosocial outcomes – A digital image analysis evaluating... Full story

Yahoo Finance • 2 days ago

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Monday afternoon with the NYSE Healthcare Index down 0.1% and the State Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 2 days ago

ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continues

Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street's revenue expectations in Q3 2026, with sales up 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.82 per share was 1.3% above analysts' consensus estimates. Is now th... Full story

Yahoo Finance • 2 days ago

AbbVie Stocks Decline 2.3% With RBC Target Increase Backing Its Immunology Transition

This article first appeared on GuruFocus. AbbVie (NYSE:ABBV) has a growth story to selland two medicines doing the heavy lifting. Shares fell 2.32% to $288.06 at 10:20 a.m. ET on November 2, even as RBC raised its price target to $330 fro... Full story

Yahoo Finance • 2 days ago

AbbVie (ABBV) Lands Phase 3 Migraine Study Win In The Lancet Neurology

AbbVie (NYSE: ABBV) reported positive Phase 3 TEMPLE trial results for QULIPTA in migraine prevention, with findings published in The Lancet Neurology. The TEMPLE study found that QULIPTA achieved superior migraine prevention efficacy comp... Full story

Yahoo Finance • 2 days ago

Brise Pharmaceuticals Announces Global License Agreement with AbbVie to Advance the Next-Generation of Migraine Therapies

BEIJING, Nov. 2, 2026 /PRNewswire/ -- Brise Pharmaceuticals Co., Ltd. (Brise) today provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under the terms of the collaboration a... Full story

Yahoo Finance • 2 days ago

The top 5 analyst questions from AbbVie’s Q3 earnings call

AbbVie's third quarter was marked by a positive market reaction, attributed to robust sales growth across its immunology and neuroscience portfolios. Management highlighted the continued momentum of key products like SKYRIZI, RINVOQ, and V... Full story

Yahoo Finance • 3 days ago

What State Street Health Care SPDR (XLV) Bought: Eli Lilly Leads on Oct. 29

This article first appeared on GuruFocus. State Street Health Care Select Sector SPDR ETF (XLV) reported $423.4 million in ETF activity last Thursday, all of it buying. The $49.10 billion fund increased all 60 of its positions and decreas... Full story

Yahoo Finance • 3 days ago

5 Most Undervalued Dividend Growth Stocks According to Hedge Funds

Dividend-paying stocks can be an important part of a long-term investment portfolio because they let investors earn steady income while also participating in the stock market's growth. Companies with established dividend policies are gener... Full story

Yahoo Finance • 5 days ago

Is Earnings Beat Altering The Investment Case For AbbVie Stock (ABBV)?

AbbVie reported third quarter 2026 sales of US$17.4b and net income of US$4.2b, raised full year revenue and adjusted EPS guidance, and approved a 5.2% quarterly dividend increase to US$1.82 per share starting with the February 16, 2027 pa... Full story

Yahoo Finance • 5 days ago

Q3 earnings round-up: AstraZeneca, AbbVie, Kenvue

Market Domination Overtime Host Jared Blikre keeps track of several stocks moving in extended-hours trading after releasing earnings results, including AstraZeneca (AZN), AbbVie (ABBV), and Kenvue (KVUE). Video Transcript 00:00 Speaker A... Full story

Yahoo Finance • 5 days ago

Midday Need to Know: Exxon beats earnings estimates, Silver falls below $50 & more

[Wall Street sign in Lower Manhattan, NYC] georgeclerk U.S. stocks continued to decline on Friday after another batch of discouraging earnings reports came from Amazon (AMZN [https://seekingalpha.com/symbol/AMZN]) and Intel (INTC [https:/... Full story

Yahoo Finance • 5 days ago

AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views

AbbVie (ABBV) raised its 2026 guidance on Friday as the biopharmaceutical company's immunology and n Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news Full access to Financial Times and MT N... Full story

Yahoo Finance • 5 days ago

AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates

AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates Pharmaceutical company AbbVie (NYSE:ABBV) met Wall Street's revenue expectations in Q3 2026, with revenue rising 10.3% year on year to $17.4 billion. Its non-GAAP profit of $3.... Full story